Pfizer's blood cancer therapy Adcetris succeeds in late-stage trial

Pfizer said on Tuesday its drug, Adcetris, extended survival in patients with the most common type of lymphoma in a late-stage study, bolstering efforts to expand the use of the treatment gained through its $43 billion purchase of Seagen.